Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeracyteVCYT -0.17%75 Debt-to-Equity is 0.03 as of Mar. 2026, which is 25% below its 10-year median of 0.04. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.33 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Veracyte ranks better than 90.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Veracyte's Debt-to-Equity or its related term are showing as below:
VCYT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.98
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Veracyte was 0.98. The lowest was 0.01. And the median was 0.04.
VCYT's Debt-to-Equity is ranked better than 90.16% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs VCYT: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Veracyte Debt-to-Equity Related Terms
Veracyte Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Veracyte's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCYT vs RDNT, SHC, BLLN: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Veracyte's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Veracyte's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (VCYT) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Veracyte and its competitors. This is 25% below median its historical median of 0.04. Over the past decade, Veracyte's Debt-to-Equity has ranged from 0.01 to 0.98. According to the industry distribution chart, Veracyte ranks #18 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 9.8%.
Is Veracyte's Debt-to-Equity too high?
Veracyte's current Debt-to-Equity of 0.03 is 25% below median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.98. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Veracyte's value of 0.03 is 90.9% below this industry median. Based on the distribution chart, Veracyte ranks #18 out of 183 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's Debt-to-Equity compare to RDNT and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #18 out of 183 companies for Debt-to-Equity. This places Veracyte in the top 10% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.33. Veracyte's value of 0.03 is 90.9% below this benchmark. Historically, Veracyte's own Debt-to-Equity has ranged from 0.01 to 0.98 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.33, Veracyte has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veracyte's current Debt-to-Equity of 0.03 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Veracyte and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veracyte's current Debt-to-Equity is 0.03, which is 25% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.33, compared to a current price of $59.14 — trading 54.3% above its estimated fair value. The current Debt-to-Equity is 0.03, which is 25% below median its 10-year median of 0.04 and 90.9% below the Medical Diagnostics & Research industry median of 0.33. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Veracyte (VCYT), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veracyte (VCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Veracyte stock appears to be overvalued.
The current stock price of $59.14 is trading 54.3% above its estimated GF Value™ of $38.33.
GuruFocus considers Veracyte to be Significantly Overvalued.
Key valuation signals for VCYT:
Debt-to-Equity: 0.03 (25% below median its 10-year median of 0.04)
GF Value™: $38.33 vs. price of $59.14 (54.3% above fair value)
Industry Position: 90.9% below the Medical Diagnostics & Research median (#18 of 183)
No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score
Get the complete analysis for VCYT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCYT has been successfully added to your 
